Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MDWD - MediWound's NexoBrid for thermal burns in children gets EMA review

MDWD - MediWound's NexoBrid for thermal burns in children gets EMA review

MediWound Ltd.

  • The European Medicines Agency (EMA) validated for review MediWound's ( NASDAQ: MDWD ) application for expanded use of NexoBrid in children aged newborn through 18 years of age for removal of eschar (dead tissue) with deep partial-and full-thickness thermal burn wounds.
  • The submission is backed by interim data from a global, phase 3 trial (CIDS - Children Innovative Debridement Study), EU phase 3 study (MW2004-11-02) and phase 2 studies conducted during the clinical development of NexoBrid.
  • NexoBrid is also under review in the U.S. for use in adults.

For further details see:

MediWound's NexoBrid for thermal burns in children gets EMA review
Stock Information
Company Name: MediWound Ltd.
Stock Symbol: MDWD
Market: NASDAQ
Website: mediwound.com
Menu
MDWD MDWD Quote MDWD Short MDWD News MDWD Articles MDWD Message Board
Get MDWD Alerts

News, Short Squeeze, Breakout and More Instantly...